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Supersized kidneys: Lessons 
from the preclinical obese kidney
VD D’Agati1 and GS Markowitz1
The worldwide prevalence of obesity continues to rise.  Obesity has been 
shown to increase the risk of both the development and the progression 
of renal failure, even after correction for other comorbid conditions.  The 
ability of nephrologists to intervene will require greater understanding 
of obesity’s renal physiologic effects. Kidney biopsies and functional 
studies performed on morbidly obese patients without overt renal 
disease who presented for bariatric surgery have helped to elucidate the 
earliest obesity-related structural and functional responses. 
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It’s a fat world after all. According to 
the most recent statistics (2003–2004) 
from the National Center for Health 
Statistics of the Centers for Disease 
Control and Prevention, two-thirds 
(66.3%) of American adults are over-
weight or obese.1 For adults age 20–39 
the prevalence of overweight or obesity 
is 57.1%, increasing to a startling 73.1% 
for those in the 40-to-59-year age group 
and 71.0% for those over age 60.1 The 
epidemic is not limited to the United 
States. According to the World Health 
Organization, the prevalence of obesity 
worldwide has increased from approxi-
mately 200 million adults in 1995 to 
over 300 million adults in 2000.2 Recent 
estimates indicate that over one billion 
adults, roughly one-ﬁfth of the world 
population, are overweight or obese.2
From those statistics has followed a 
dramatic increase in the prevalence of 
metabolic syndrome, including hyper-
tension, dyslipidemia, and insulin resist-
ance. What is more, obesity has been 
found to compound the risk for chronic 
kidney disease in diverse renal settings. 
Hsu et al. have demonstrated that with 
each gradient increase in body mass 
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index (BMI), there is a greater relative 
risk of end-stage renal disease: 1.87 for 
overweight individuals, 3.57 for those 
with class 1 obesity, 6.12 for those with 
class 2, and 7.07 for those with class 3 
(morbid) obesity.3 These associations 
remain strong even after adjustment 
for obesity-related comorbid condi-
tions such as diabetes and hypertension. 
Similarly, Fox et al. have reported a 23% 
increase in the odds of development of 
chronic kidney disease for each stand-
ard deviation increase in BMI, even 
after adjustment for age, sex, baseline 
glomerular filtration rate, smoking, 
and diabetes.4 A recent metaanalysis has 
concluded that obesity is a strong risk 
factor for the development and progres-
sion of chronic kidney disease.5 Obes-
ity has well-recognized eﬀects on renal 
hemodynamics that promote progres-
sive renal disease. Nephrologists’ abil-
ity to intervene will depend on a better 
understanding of the physiologic basis 
for this increased risk.
Serra et al.6 (this issue) provide insight 
into the early obesity-induced renal 
physiologic and pathologic responses. 
Historically, the ﬁrst studies on obesity-
related renal disease were case reports 
at autopsy in morbidly obese patients.7 
Later, biopsy-based studies of obesity-
related focal sclerosis helped to deﬁne 
the clinical-pathologic features of this 
entity.8 All these studies focused on 
patients with clinically overt renal dis-
ease. The study by Serra et al.6 has the 
advantage of performing systematic 
renal biopsies on all morbidly obese 
patients without overt renal manifesta-
tions who presented for bariatric surgery 
to a center in Barcelona, Spain. Thus, it 
oﬀers a rare, if not unique, window on 
the preclinical obese kidney in patients 
who would otherwise not have reached 
a threshold for renal biopsy.
Not surprisingly, the investigators 
found a variety of renal structural 
abnormalities in patients with mor-
bid obesity and no overt clinical renal 
disease. Glomerular hypertrophy 
(glomerulomegaly) was present in 38% 
of morbidly obese patients, compared 
with only 2.5% of normal-BMI controls. 
There was also an increased prevalence 
of focal segmental glomerulosclerosis, 
global glomerulosclerosis, mesangial 
sclerosis, mesangial hypercellularity, 
and podocyte hypertrophy. By multi-
variate analysis, only BMI was associ-
ated with development of glomerular 
lesions, independently of hypertension 
and hyperglycemia, which were present 
in 46% and 14% of patients, respectively. 
Thus, among patients with morbid obes-
ity (BMI >40 kg/m2), the degree of ele-
vation of BMI per se confers increased 
risk of developing glomerular lesions. 
These ﬁndings are consistent with recent 
evidence that the quantity of excess 
adipose tissue itself may exert systemic 
eﬀects through the secretion of a variety 
of hormones and cytokines, including 
leptin, adiponectin, tumor necrosis 
factor-α, angiotensinogen, interleukin-
6, and C-reactive protein.9
One of the most interesting find-
ings to emerge from this study is that 
glomerulomegaly was more prevalent 
in extremely obese patients with sleep 
apnea (51%) than without sleep apnea 
(28%). This difference was statisti-
cally signiﬁcant, suggesting a potential 
pathogenetic link between sleep apnea 
and the development of glomerular 
hypertrophy. Sleep apnea activates the 
sympathetic nervous system, promot-
ing systemic hypertension and activa-
tion of the renin–angiotensin axis, in 
turn leading to glomerular capillary 
hypertension.10,11 In fact, patients with 
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obesity-related glomerulopathy have 
been noted to have hyperplasia of the 
juxtaglomerular apparatus on renal 
biopsy.8 Obese patients have elevations 
of both renal plasma ﬂow and glomeru-
lar filtration rate that exceed those of 
controls by 31% and 51%, respectively,12 
thereby promoting glomerular capillary 
hypertension. Taken together, these stud-
ies suggest that weight loss could have a 
beneﬁcial eﬀect on preservation of renal 
function, independent of other interven-
tions such as pharmacologic blockade of 
the renin–angiotensin system or control 
of systemic hypertension. Drastic weight 
loss after bariatric surgery has led to 
reductions in glomerular ﬁltration rate 
and albuminuria within 12 months of 
surgery in most morbidly obese patients, 
supporting the potential reversibility of 
these functional alterations.13 The results 
of the study by Serra et al.6 also suggest 
that aggressive treatment of sleep apnea 
syndrome, particularly in obese patients 
in whom weight loss is unattainable, is 
likely to have a beneﬁcial eﬀect on pro-
teinuria and renal function.
The authors also found that 41% of 
extremely obese patients had micro-
albuminuria and 4% had albuminu-
ria (defined as albuminuria >300 and 
<500 mg per 24 hours). Thus, nearly half 
had early functional markers of glomeru-
lar disease. Longer prospective follow-up 
of such patients is needed to determine 
whether the subset with microalbu-
minuria is more at risk for develop-
ment of obesity-related focal segmental 
glomerulosclerosis, analogous to the role 
of microalbuminuria in detection of dia-
betic patients at risk for development of 
overt diabetic nephropathy.
Some additional comments regarding 
the study by Serra et al.6 are worth con-
sidering. First, because no patients with 
class 1 (BMI 30–34.9) or class 2 (BMI 
35–39.9) obesity were included, the 
study cannot address the eﬀects of these 
lower grades of obesity on the develop-
ment of glomerular disease. Second, the 
deﬁnition of ‘glomerular lesions’ (that 
is, mesangial sclerosis, mesangial pro-
liferation, or podocyte hypertrophy) 
is nonspeciﬁc and diﬃcult to quantify, 
making it unlikely to achieve high inter-
observer agreement. Third, the ﬁnding 
of mesangial sclerosis is also common 
in smokers,14 who constituted half of the 
extremely obese patients in this study. 
Finally, a very interesting but under-
emphasized statistic is that 9 of the 139 
morbidly obese patients screened for 
bariatric surgery were excluded from 
the study because they had renal insuf-
ficiency or proteinuria (>500 mg per 
day). Although the sample size is small, 
these data suggest a 6.5% prevalence of 
overt renal disease among patients with 
morbid obesity.
In summary, the kidneys of morbidly 
obese patients without overt clinical renal 
disease harbor a variety of predominantly 
glomerular lesions. Even when clinically 
silent, the physiologic eﬀects of obesity 
can produce structural renal changes. 
We must conclude that those patients 
who develop overt proteinuria and renal 
insuﬃciency are just the tip of the iceberg 
in a disease of epidemic proportions.
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